EZLATAMIG
UNII 8Q9RSN73K7
Substance Identification & Data
This profile provides standardized clinical and technical data for Ezlatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8Q9RSN73K7.
Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 3081327-08-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.
8Q9RSN73K7
3081327-08-1
N/A
Detailed Substance Profile
Preferred Name
EZLATAMIG
Official standardized name for this substance within the FDA UNII nomenclature system.
INN ID
14109
Sequential identifier assigned via the WHO International Nonproprietary Name program.
Substance Type
Ezlatamig
ISO 11238 classification category (e.g., Chemical, Polymer, Protein).
Synonyms and Nomenclature
This section provides a complete list of nomenclature and identifier mappings for Ezlatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.
FDA Official Name
Ezlatamig
Common Names & Synonyms
Immunoglobulin G1, bispecific [42-cysteine,233-cysteine,246-serine,260-alanine,261-alanine,291-serine,392-tryptophan], anti-(human CD3 antigen) (synthetic human monoclonal C3CRB73 single-chain variable fragment VL-(peptide linker (synthetic 18-amino acid))-VH) fusion protein with immunoglobulin G1 (human γ1-chain C-region C-terminal fragment), (252→229′),(255→232′)-bis(disulfide) with immunoglobulin G1 [237-alanine,238-alanine,268-serine,369-serine,371-alanine,410-valine,438-arginine,439-phenylalanine] anti-(human calreticulin) (synthetic human monoclonal C3CRB73 γ1-chain), (223′→217′′)-disulfide with synthetic human monoclonal C3CRB73 κ-chain
ezlatamig [INN]
heavy chain H-gamma1 humanized anti-CALR (hole) (H) (1-450) [VH (Homo sapiens IGHV3-66*01 (80.4%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.14] (26-33.51-57.96-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v33 CH3 S22, A24, V86 (hole), 10-G1v83 CH3 R115, F116 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 L1.3>A (237), L1.2>A (238), D27>S (268) (234-343), CH3 E12 (359), M14 (361), T22>S (369), L24>A (371), Y86>V (410), H115>R (438), Y116>F (439) (344-448), CHS (449-450)) (121-450)], (223-217')-disulfide with light chain L-kappa humanized anti-CALR (1'-217') [V-KAPPA (Homo sapiens IGKV1-33*01 (82.2%) -IGKJ4*01 (100%), CDR-IMGT [8.3.10] (27'-34'.52'-54'.91'-100')) (1'-110') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (156'), V101 (194')) (111'-217')]; heavy chain scFvkh humanized and Homo sapiens anti-CD3E -G1(h-CH2-CH3) (knob) (H'') (1''-473'') [scFvkh humanized and Homo sapiens anti-CD3E, 11-scFv-v3 C48(VL)-C10 linker, C13 linker-C120 (VH) (1''-241'') [V-KAPPA (Homo sapiens IGKV1-39*01 (85.3%) -IGKJ2*01 (100%), CDR-IMGT [6.3.9] (27''-32''.50''-52''.89''-97'') K48>C (42'')) (1''-107'') -18-mer (triglycyl-seryl-diglycyl-seryl-diglycyl-cysteinyl C10 (117'')-diprolyl-cysteinyl C13 (120'')-diglycyl-seryl-diglycyl) linker (108''-125'') -VH (Homo sapiens IGHV3-21*01 (89.8%) -IGHD -IGHJ4*01 (92.9%) Q120>C (233''), CDR-IMGT [8.8.9] (151''-158''.176''-183''.222''-230'')) (126''-241'')] -G1(h-CH2-CH3) Homo sapiens IGHG1*03v h-CH2-CH3-CHS, nG1m1 CH3 E12, M14, 15-G1v37 h S5, 6-G1v14-67 CH2 A1.3, A1.2, S27, 14-G1v32 CH3 W22 (knob) [(hinge 1-15 C5>S (246'') (242''-256''), CH2 L1.3>A (260''), L1.2>A (261''), D27>S (291'') (257''-366''), CH3 E12 (382''), M14 (384''), T22>W (392'') (367''-471''), CHS (472''-473'')) (242''-473'')]]; dimer (229-252'':232-255'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa
immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3), anti-[Homo sapiens CALR (calreticulin, autoantigen Ro, RO, Sjögren syndrome antigen A, SSA)] and anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4)], humanized and Homo sapiens monoclonal antibody, bispecific
